ArticleScientific reports2025
MIR155HG promotes metastasis and cisplatin resistance of cervical cancer cells by regulating the miR-409-3p and ZEB1 axis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Therapy resistance-related ncRNAs in cervical cancer: biomarkers and therapeutic targets.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026Review
- The role of long non-coding RNAs in therapy resistance of cervical cancer and therapeutic potential.Frontiers in cell and developmental biology · 2026Review
- Circ_CIT Promotes Nasopharyngeal Carcinoma Progression and Macrophage M2 Polarization Through miR-409-3p/ZEB1 Axis.Cancer management and research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Long non-coding RNA (lncRNA) exhibits a crucial role in multiple human malignancies. The expression of lncRNA MIR155HG, reportedly, is aberrantly up-regulated in several types of tumors. In this research, we studied the role and mechanism of MIR155HG in the progression of cervical cancer (CC). We analyzed the expression pattern of MIR155HG in CC patients using public database TCGA, and overexpressed its expression in HeLa cells to explore its cellular functions. Cellular phenotype experiments were conducted to assess the influence of MIR155HG on HeLa cells, including proliferation, cell cycle, migration, invasion, and cisplatin sensitivity. Then we evaluated the impact on epithelial-mesenchymal transition (EMT) of MIR155HG and identified the underlying regulatory mechanism. We found that MIR155HG was highly expressed and positively correlated with overall survival (OS) prognosis results in CC patients. Overexpression of MIR155HG (MIR155HG-OE) demonstrated higher proliferation and migration levels in HeLa cells, while MIR155HG inhibited the apoptosis rate of HeLa cells. Meanwhile, we found MIR155HG can reduce the effect of cisplatin sensitivity on HeLa cells. Besides this, MIR155HG-OE significantly changed the expression pattern of EMT biomarkers, including ZEB1, TWIST1, Vimentin, N-cadherin, and E-cadherin. To explore the underlying mechanism, we found MIR155HG can promote ZEB1 expression by sponging miR-409-3p, forming a competitive endogenous RNA system to inhibit cisplatin sensitivity. In this study, we deeply explored the molecular and cellular functions of MIR155HG in CC cells. Our results highlight the important role and potential targeting value of MIR155HG in CC pathogenesis and development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.